Casey Lynch, Cortexyme CEO
Cortexyme switches direction, announces layoffs after FDA slaps hold on dark horse Alzheimer’s candidate
Cortexyme’s efforts to develop an outside-the-box treatment for Alzheimer’s took a significant hit Tuesday.
The biotech announced the FDA has put a full clinical hold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.